Received Apr 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 54RR9 | — |
two patients of 15 years of age received 1st Bexsero dose on 2022, and the 2nd dose on 12-Mar-2026. The patients are twins; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 15-year-old male patient who received Men B NVS (Bexsero) (batch number 54RR9) for prophylaxis. Previously administered products included Bexsero (1st dose received on 2022). On 12-MAR-2026, the patient received the 2nd dose of Bexsero. On 12-MAR-2026, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too long (Verbatim: two patients of 15 years of age received 1st Bexsero dose on 2022, and the 2nd dose on 12-Mar-2026. The patients are twins). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-APR-2026 This case US2026043407 was reported by same reporter for different patient. The batch number was not provided and a request for this information has been made; Sender's Comments: US-GSK-US2026043407:Same reporter/Different patient